GENENTECH AND THE USE OF LUCENTIS AND AVASTIN FOR OPHTHALMIC PURPOSES

Early day motion 2823, tabled 6 March 2012 by John Hemming (Liberal Democrat). Signed by 3 members.

That this House notes the positive clinical results from the use of Lucentis for ophthalmic uses; further notes that Avastin has also been found to be efficacious for similar purposes; further notes that Genentech, the manufacturer of both, has resisted the clinical use of Avastin in an ophthalmic setting; queries whether the fact that Lucentis has a cost of the order of 40 times the cost of Avastin is a matter which is influencing the manufacturer; and calls on Health Ministers to enter into discussions with Genentech as to how most effectively patients in England can have their ophthalmic issues properly medicated.

Signatures by party: Liberal Democrat 2, Labour 1.